Jan 17 2025

Medicare selects 15 drugs for second round of price negotiations, including semaglutide

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.
On Jan. 17, CMS announced it will commence negotiations with pharmaceutical companies to lower prices for Medicare Part D coverage for a wide range of drugs to treat multiple forms of cancer, type 2 diabetes, asthma and more. Negotiations will take place this year, with negotiated prices going into effect in 2027.
“Today, I’m proud to announce that my administration has selected the next 15 drugs for Medicare drug price negotiation,” President Joe

Read More

From Healio.com RHEUMATOLOGY • • 0

Jan 17 2025

Medicare selects 15 drugs for second round of price negotiations, including semaglutide

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.
On Jan. 17, CMS announced it will commence negotiations with pharmaceutical companies to lower prices for Medicare Part D coverage for a wide range of drugs to treat multiple forms of cancer, type 2 diabetes, asthma and more. Negotiations will take place this year, with negotiated prices going into effect in 2027.
“Today, I’m proud to announce that my administration has selected the next 15 drugs for Medicare drug price negotiation,” President Joe

Read More

From Healio.com ENDOCRINOLOGY • • 0

Jan 17 2025

Rheumatologist Accused of Sex Abuse by Over 200 Patients Is Indicted on Rape Charges

(MedPage Today) -- A grand jury in Massachusetts has indicted a rheumatologist who is accused of sexually assaulting more than 200 former patients over a period of more than a decade. The patients sued Derrick Todd, MD, who has been accused of...

Read More

From Med Page Today • • 0

Jan 17 2025

The year in lipids: Progress in Lp(a) management and a blow to the ‘HDL hypothesis’

In 2024, there were numerous trials and a few regulatory moves related to advancements in lipid management for the prevention of major adverse CV events.
At the Cardiometabolic Health Congress in October, Christie M. Ballantyne, MD, FACC, FACP, FAHA, FNLA, chief of the section of cardiovascular research and professor of medicine at Baylor College of Medicine, discussed the following developments in lipidology, in no particular order.
At the 2024 National Lipid Association Scientific Sessions, Ballantyne presented the results of the phase 3 BALANCE trial of olezarsen (Tryngolza, Ionis

Read More

From Healio.com CARDIOLOGY • • 0

Jan 17 2025

New error grid better tailored to assess CGM accuracy

A new error grid to assess the accuracy of glucose measurements could give continuous glucose monitor manufacturers and regulatory agencies such as the FDA a better understanding of how accurate their devices are.
An international panel of 94 experts in glucose monitoring from all six continents unveiled the Diabetes Technology Society error grid in a paper published in the Journal of Diabetes Science and Technology. The new error grid is a successor to the society’s surveillance error grid that was published in 2014. The new grid was created to better define risk zones and make the grid

Read More

From Healio.com ENDOCRINOLOGY • • 0